Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
Belite Bio is preparing to file its Stargardt disease drug candidate tinlarebant in Japan within three months of its US submission as the biotech gears up to bring what could become the first treatment for the rare inherited retinal disorder…
To read the full story
Related Article
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- Belite Bio Files Stargardt Drug Tinlarebant in Japan
September 9, 2026
- Belite Bio Japan Launches Stargardt Disease Awareness Initiative
August 3, 2026
- Xevinapant Earns Sakigake Tag, 6 APIs Get Orphan Status
June 20, 2024
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





